News

The company’s move from its original 7,200 square foot location in Farmingdale, New York means that it will be able to manufacture new products, create more jobs, and

The trial failed to meet the primary endpoint of improved disease free survival (DFS) compared to single agent therapy with trastuzumab. The company said that the safety profile

US subsidiary of the company Eisai Inc. is marketing the product based on having received exclusive marketing rights from Helsinn Healthcare for the US. The company said that

The 24-patient five-week, randomized, double-blind Phase IIb trial is being conducted by Accumed Research Associates under the direction of Principal Investigator Mitchell Efros. SUGARDOWN is the company’s currently

Benitec Biopharma CEO and managing director Peter French said that the commencement of this clinical trial of TT-034 represents a landmark in the company’s history. "The trial is

Current investors Atlas Venture and Johnson & Johnson Development (JJDC) led the financing round. Rodin will use the new funds to advance its pipeline of selective epigenetic modulators

Mylan received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prophylaxis

Spectrum Pharmaceuticals chairman and CEO Rajesh Shrotriya said that SPI-2012 is the highest priority drug in the company’s pipeline because of its unique technology, and its potential to

Prior to the meeting with the MPA on 26 May 2014, InSite Vision had submitted substantial preliminary BromSite information to the Agency including CMC (chemistry, manufacturing, and controls)